Middle East and Africa Migraine Treatment Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 04-Jan-2020 | No of Pages: 100


USD 3995
USD 5795

Publish Date:


Total pages:


Middle East and Africa migraine treatment market is projected to register a CAGR of 8.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Middle East & Africa Migraine Treatment Market, By Types of Migraine (Episodic, Migraine with Aura, Chronic and Others), Treatment (Acute/Abortive Treatment, Preventive/Prophylactic Treatment, Non-Pharmacological Therapies, Devices), Route of Administration (Oral, Parenteral, Nasal Sprays, Others), Product Type (Prescription, Over the Counter), Type (Branded, Generic), End User (Hospitals, Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, UAE, Egypt, Kuwait, Israel and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the Middle East and Africa migraine treatment market are:

• Availability of large number of generic drugs
• Development of novel drugs
Market Players:
The key market players for Middle East and Africa migraine treatment market are listed below:
• Amgen Inc
• GlaxoSmithKline plc
• Novartis AG
• Bayer AG
• Allergan
• Abbott
• AstraZeneca
• Bausch Health Companies Inc
• Boehringer Ingelheim International GmbH
• Dr. Reddy’s Laboratories Ltd
• Lundbeck
• Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc.)
• Pfizer Inc
• Sun Pharmaceutical Industries Ltd

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.